RDY - Dr. Reddy's Laboratories Limited

NYSE - NYSE Delayed Price. Currency in USD

Dr. Reddy's Laboratories Limited

8-2-337, Road No. 3
Banjara Hills
Hyderabad 500034
91 40 4900 2900

IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees21,966

Key Executives

NameTitlePayExercisedYear Born
Mr. Gunupati Venkateswara PrasadCo-Chairman, MD & Member of Management CouncilN/AN/A1960
Mr. Kallam Satish ReddyChairman & Member of the Management CouncilN/AN/A1967
Mr. Erez IsraeliCEO & Member of the Management CouncilN/AN/A1968
Mr. Saumen ChakrabortyPres, CFO, Global Head of IT & Bus. Process Excellence and Member of the Mgmt CouncilN/AN/A1961
Mr. M. V. RamanaCEO & Head of Branded Markets - India & Emerging Countries and Member of Management CouncilN/AN/A1969
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. It also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and manufacture of differentiated formulations for dermatology and neurology therapeutic areas. As of March 31, 2019, it had six late stage projects at various stages of development. The company's therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company also offers diabetes nutrition drink under the Celevida brand name. It has collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology. Dr. Reddy's Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.

Corporate Governance

Dr. Reddy's Laboratories Limited’s ISS Governance QualityScore as of October 4, 2019 is 1. The pillar scores are Audit: 7; Board: 1; Shareholder Rights: 1; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.